Anti-inflammatory Treatment for Seemingly Non-inflammatory Disorders. Editorial

Affiliations

Editorial

Yoshiro Maru. Endocr Metab Immune Disord Drug Targets. 2015.

. 2015;15(2):82.

doi: 10.2174/187153031502150522123335.

¹ Department of Pharmacology Tokyo Women's Medical University 8-1 Kawada-cho, Shinjuku-ku Tokyo 162-8666 Japan. ymaru@research.twmu.ac.jp.

No abstract available

Similar articles

Editorial: update on inflammatory targets modulating atherogenesis.
Carbone F, Mach F, Montecucco F. Carbone F, et al. Curr Drug Targets. 2015;16(4):282-3. doi: 10.2174/138945011604150406164447. Curr Drug Targets. 2015. PMID: 25859799 No abstract available.
Curcumin targets in inflammation and cancer.
Deguchi A. Deguchi A. Endocr Metab Immune Disord Drug Targets. 2015;15(2):88-96. doi: 10.2174/1871530315666150316120458. Endocr Metab Immune Disord Drug Targets. 2015. PMID: 25772169 Review.
Inflammation and atherosclerosis: what is on the horizon?
Ruparelia N, Choudhury R. Ruparelia N, et al. Heart. 2020 Jan;106(1):80-85. doi: 10.1136/heartjnl-2018-314230. Heart. 2020. PMID: 31843811 Review. No abstract available.
Novel anti-inflammatory therapies for the treatment of atherosclerosis.
Khan R, Spagnoli V, Tardif JC, L'Allier PL. Khan R, et al. Atherosclerosis. 2015 Jun;240(2):497-509. doi: 10.1016/j.atherosclerosis.2015.04.783. Epub 2015 Apr 18. Atherosclerosis. 2015. PMID: 25917947 Review.
Immune-mediated inflammation across disease boundaries: breaking down research silos.
Buckley CD, Chernajovsky L, Chernajovsky Y, Modis LK, O'Neill LA, Brown D, Connor R, Coutts D, Waterman EA, Tak PP. Buckley CD, et al. Nat Immunol. 2021 Nov;22(11):1344-1348. doi: 10.1038/s41590-021-01044-7. Nat Immunol. 2021. PMID: 34675389 No abstract available.